• Explore /
  • Poster
  • / Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).

Olaparib (O) in advanced triple negative breast cancer (aTNBC) patients (pts) with BRCA1/2 promoter methylation: GEICAM/2015-06 study (COMETA-Breast).

Abstract Poster

Authors

null

Juan De La Haba

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)–H. Universitario Reina Sofía, Universidad de Córdoba. GEICAM Spanish Breast Cancer Group, Cordoba, Spain

Juan De La Haba , Antonio Anton , Vanesa Quiroga , Angel Guerrero , Raquel Andrés , Mireia Mele , Santiago Gonzalez- Santiago , Jose Alejandro Perez-Fidalgo , Teresa Ramon y Cajal , Maria Jose Escudero , Susana Bezares , Rosalia Caballero , Federico Rojo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT03205761

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 1093)

DOI

10.1200/JCO.2023.41.16_suppl.1093

Abstract #

1093

Poster Bd #

314

Abstract Disclosures

Similar Posters

First Author: Elias Chandran

First Author: Alistair E. Ring

First Author: Joseph W. Kim

First Author: Navid Hafez